CAR T CELL THERAPY – NOVEL IMMUNOTHERAPY FOR REFRACTORY MALIGNANCIES

Dr. Abhishek Pathak*, Dr. Anvesh Rathore, Dr. Alpana Gupta, Dr. Rajan Kapoor and Dr. Subhash Ranjan

ABSTRACT

The number of cases of cancer seems to be increasing be it due to better investigating approaches, more awareness or the sheer longevity of cancer patients. The management of early-stage cancer seems to be encouraging but it is the advanced stage cancer whose treatment with the prevailing modalities of therapy be it surgery, cytotoxic chemotherapy or radiotherapy seems to be frustrating. Sooner or later these cancers seem to relapse and many times with more vengeance and it is at this particular time when we don't have much to offer except palliative therapy. The failure of cytotoxic chemotherapy in advanced stage, lack of sustained remission and the toxicity profile of cytotoxic chemotherapy prompted researchers to use the body's immune mechanism to fight against cancer, hoping that the relapses would be more sustained and toxicities fewer. Hence, the concepts of Immunotherapy were born. Chimeric Antigen Receptor T cell (CAR-T Cell therapy) therapy is the one of the latest immunotherapies with a very promising future in the setting of Refractory or Relapse Malignancies.[1]

Keywords: .